An international, interdisciplinary research team led by Prof. Jakob N. Kather from the Else Kröner Fresenius Center (EKFZ) for Digital Health at TUD Dresden University of Technology analyzed seven ...

Lyla J. Stanland et al, A first-in-class EGFR-directed KRAS G12V selective inhibitor, Cancer Cell (2025). DOI: 10.1016/j.ccell.2025.05.016 Provided by University of North Carolina Health Care ...

The new technology incorporates novel compositions of inverted RNAi molecules that have shown a marked ability to co-silence mutated KRAS and over-expressed MYC. RNA interference (RNAi) is a ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the ...

5. “Negligible value currently attributed to technology platform”: RXi’s current market cap is about $10 million and its enterprise value just over $5 million.